Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 DDI of CBD and Morphine in Recreational Opioid Users
NCT05143424Phase 1Recruiting
- Sponsor
- National Institute on Drug Abuse
- Start
- Nov 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-blind trial of cannabidiol in opioid use disorder (OUD) (2 arms), sponsored by National Institute on Drug Abuse. Primary endpoints: Maximum Plasma Concentration (Cmax) of Morphine at 3 days, Area Under the Curve (AUC 0-t) of Morphine and Glucuronide Conjugates at 3 days and 1 more. Started Nov 2021; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT05143424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05143424.